Background Coronavirus disease 2019 (COVID-19) is still an ongoing entity and every day we face new sequalae of the disease. We hereby present surgical results of patients who are treated for post-COVID chronic thromboembolic pulmonary hypertension.

Methods Data were collected among patients who underwent pulmonary endarterectomy and had a diagnosis of post-COVID chronic thromboembolic pulmonary hypertension. All data were retrospectively reviewed from a prospectively conducted database. Operative mortality was described as death in hospital or within 30 days of surgery.

Results Eleven patients (seven males, four females; median age, 52 [22–63] years) were identified. Pulmonary vascular resistance improved significantly from 572 dyn/s/cm⁻⁵ (240–1,192) to 240 (195–377) dyn/s/cm⁻⁵ (p < 0.005). Significant difference was also detected in median mPAP, as it decreased from 40 mm Hg (24–54) to 24 mm Hg (15–36) following surgery (p < 0.005). Mortality was observed in one patient due to sepsis on the fifth postoperative day. Median time from COVID-19 disease to surgery was 12 months (6–24). Median length of hospital stay of the survivors was 10 days (8–14).

Conclusions In the new era of chronic thromboembolic pulmonary hypertension, hybrid approach including surgery, balloon pulmonary angioplasty, and medical treatment has been recommended. pulmonary endarterectomy is still the only curative treatment when the disease is surgically accessible. We hereby report the first publication of post-COVID chronic thromboembolic pulmonary hypertension patients who were surgically treated. As we see a lot of long-term symptoms and clinical manifestations in patients who had COVID-19, we should always remember chronic thromboembolic pulmonary hypertension in the differential diagnosis.

背景 2019 年冠状病毒病 (COVID-19) 仍然是一个持续存在的实体，我们每天都会面临该疾病的新后遗症。我们在此介绍接受新冠肺炎后慢性血栓栓塞性肺动脉高压治疗的患者的手术结果。

方法 收集接受肺动脉内膜切除术并诊断为新冠肺炎后慢性血栓栓塞性肺动脉高压的患者的数据。所有数据均来自前瞻性数据库进行回顾性审查。手术死亡率被描述为在医院或手术后 30 天内死亡。

结果 确定了 11 名患者（7 名男性，4 名女性；中位年龄，52 [22-63] 岁）。^{肺血管阻力从 572 dyn/s/cm -5} (240–1,192)显着改善至 240 (195–377) dyn/s/cm ^-5 ( p  < 0.005)。中位 mPAP 也存在显着差异，手术后它从 40 mm Hg (24-54) 降至 24 mm Hg (15-36) ( p  < 0.005)。术后第五天观察到一名患者因败血症死亡。从 COVID-19 患病到手术的中位时间为 12 个月 (6-24)。幸存者的住院时间中位数为 10 天 (8-14)。

结论 在慢性血栓栓塞性肺动脉高压的新时代，手术、球囊肺动脉成形术和药物治疗相结合的治疗方法受到推荐。当可以通过手术治疗该疾病时，肺动脉内膜切除术仍然是唯一的治疗方法。我们在此报告首例接受手术治疗的新冠肺炎后慢性血栓栓塞性肺动脉高压患者的出版物。由于我们在 COVID-19 患者中看到许多长期症状和临床表现，因此在鉴别诊断中我们应始终记住慢性血栓栓塞性肺动脉高压。